Krsnaa Diagnostics Ltd

AI
Krsnaa Diagnost. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Krsnaa Diagnostics Ltd

₹ 548 -0.51%
25 Sep - close price
krsnaadiagnostics.com BSE: 543328 NSE: KRSNAA
About

Krsnaa Diagnostics Ltd provides a range of technology-enabled diagnostic services such as imaging, clinical laboratory, and teleradiology services to hospitals, medical colleges, and community health centers across India with an extensive network across non-metro and lower-tier cities and towns.[1]

Key Points

Business Profile:[1]
Krsnaa Diagnostics Ltd is one of India’s largest integrated diagnostic service providers with a Pan-India presence in Radiology and Pathology. It has established a presence across 18 states and union territories through partnerships with government hospitals and operates 190 CT and MRI centers, 140 pathology laboratories, 4,000+ patient collection centres, and 1,501 tele-radiology centres as of Q3 FY26.

Website BSE NSE
  • Market Cap ₹ 1,779 Cr.
  • Current Price ₹ 548
  • High / Low ₹ 849 / 502
  • Stock P/E 18.0
  • Book Value ₹ 306
  • Dividend Yield 0.36 %
  • ROCE 12.7 %
  • ROE 10.9 %
  • Face Value ₹ 5.00
Edit ratios

Pros

Cons

  • The company has delivered a poor sales growth of 11.8% over past five years.
  • Promoter holding is low: 27.1%
  • Company has a low return on equity of 9.26% over last 3 years.
  • Company has high debtors of 163 days.
  • Working capital days have increased from 25.4 days to 65.9 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Service Provider

Part of BSE Healthcare BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
132 147 152 159 163 179 165 175 176 183 159 173 211
100 116 113 116 120 126 117 121 126 125 112 116 154
Operating Profit 32 31 38 43 43 52 48 53 50 58 48 57 57
OPM % 24% 21% 25% 27% 26% 29% 29% 31% 29% 32% 30% 33% 27%
4 4 4 4 7 5 9 4 4 4 4 31 7
Interest 2 3 4 7 5 6 6 7 6 8 8 12 15
Depreciation 16 18 21 18 21 22 23 22 22 23 23 22 28
Profit before tax 19 14 17 22 24 28 28 29 26 31 21 54 22
Tax % 18% 20% 20% 17% 23% 23% 24% 28% 26% 24% 22% 20% 26%
15 11 14 18 18 22 22 21 20 23 16 43 16
EPS in Rs 4.86 3.60 4.21 5.70 5.63 6.80 6.69 6.53 6.03 7.16 5.08 13.37 4.88
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
36 57 108 147 258 396 455 464 590 682 691 726
35 42 169 87 373 302 320 340 444 485 478 507
Operating Profit 0 15 -62 60 -114 94 135 124 146 197 213 219
OPM % 0.6% 26% -57% 41% -44% 24% 30% 27% 25% 29% 31% 30%
3 4 3 2 13 265 15 19 17 26 43 47
Interest 6 6 8 16 25 26 18 8 16 25 34 42
Depreciation 5 10 18 26 32 37 41 54 75 88 90 96
Profit before tax -7 2 -84 21 -158 295 90 82 72 110 132 128
Tax % 6% 8% -29% 40% -29% 37% 21% 23% 19% 24% 22%
-8 2 -60 12 -112 185 71 64 59 83 103 99
EPS in Rs -15.05 4.01 -116.54 24.15 -216.83 284.73 22.52 20.23 18.14 25.65 31.65 30.49
Dividend Payout % -0% -0% -0% -0% -0% -0% 11% 14% 14% 11% 6%
Compounded Sales Growth
10 Years: 35%
5 Years: 12%
3 Years: 14%
TTM: 5%
Compounded Profit Growth
10 Years: 31%
5 Years: -11%
3 Years: 17%
TTM: 17%
Stock Price CAGR
10 Years: %
5 Years: -7%
3 Years: -7%
1 Year: -31%
Return on Equity
10 Years: %
5 Years: 10%
3 Years: 9%
Last Year: 11%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 5 5 5 5 6 16 16 16 16 16
Reserves 4 6 43 -217 -17 671 727 799 877 976
131 102 330 246 474 41 32 160 202 531
24 63 115 596 146 149 134 197 188 295
Total Liabilities 163 176 493 630 609 877 909 1,172 1,283 1,818
59 116 223 275 309 386 471 647 668 651
CWIP 20 6 42 9 4 28 25 10 3 208
Investments 0 0 0 0 0 0 0 0 32 58
85 53 228 345 297 463 413 514 581 902
Total Assets 163 176 493 630 609 877 909 1,172 1,283 1,818

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
59 61 38 119 129 75 24 89 134
-53 -201 -77 -67 -241 -109 -129 -102 -391
-37 145 6 20 176 -33 84 14 278
Net Cash Flow -31 4 -33 71 64 -66 -20 1 22
Free Cash Flow 6 -42 -39 50 -2 -59 -169 -21 -80
CFO/OP 410% 114% -42% 134% 100% 71% 30% 55% 75%

Ratios

Standalone / View Consolidated

Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 87 91 140 87 69 48 59 110 152 163
Inventory Days 21 24 89
Days Payable 76 99 878
Cash Conversion Cycle 32 15 -650 87 69 48 59 110 152 163
Working Capital Days -428 -119 -234 -133 -82 -21 16 -18 28 66
ROCE % 7% -65% 129% 18% 12% 10% 13% 13%

Insights

In beta
Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Patients Served
million patients

Log in to view insights

Please log in to see hidden values.

Login
Tests Performed
million tests
CT/MRI Centres (Radiology)
count
Pathology Labs (Processing + Reference)
count
Patient Collection Centres
count
NABH Accredited Radiology Centres
count
NABL Accredited Pathology Labs
count
Retail Touch Points
count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
27.79% 27.03% 27.03% 27.17% 27.17% 27.24% 27.24% 27.11% 27.11% 27.11% 27.11% 27.11%
3.68% 3.44% 3.34% 3.33% 3.63% 4.04% 3.55% 3.40% 3.66% 4.17% 3.91% 4.28%
18.73% 16.59% 15.37% 15.26% 15.86% 14.46% 14.26% 14.24% 14.96% 13.85% 13.89% 14.51%
49.79% 52.94% 54.27% 54.23% 53.34% 54.27% 54.94% 55.25% 54.27% 54.86% 55.09% 54.08%
No. of Shareholders 60,66557,23256,45855,91453,51952,79953,55954,26252,11752,38053,02253,625

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls